Pomerantz Law Firm Encourages ImmunityBio Investors to Join Class Action Lawsuit

Investor Alert: Join the Class Action Against ImmunityBio, Inc.

The Pomerantz Law Firm has recently announced crucial information for investors in ImmunityBio, Inc., a biotechnology company listed on NASDAQ under the ticker symbol IBRX. If you have experienced financial losses resulting from your investments in ImmunityBio, it is vital to be aware of an ongoing class action lawsuit that seeks to address potential securities fraud and misconduct by the company's management.

Overview of the Class Action Lawsuit

Investors are being invited to join this class action lawsuit filed by Pomerantz LLP, which specializes in corporate, securities, and antitrust litigation. The firm has a long-standing reputation for fighting on behalf of investors and has achieved significant settlements in various cases over the years. Should you be interested in participating as a Lead Plaintiff, you must act quickly, as the deadline for applications is May 26, 2026.

The lawsuit arises amidst serious allegations that ImmunityBio and some of its officers may have engaged in unlawful business practices, specifically related to securities fraud. As per the details shared by Pomerantz, these allegations have emerged from significant actions made by the U.S. Food and Drug Administration (FDA), which had previously warned the company regarding misleading promotions related to its cancer drug, Anktiva.

Recent Developments

On March 13, 2026, the FDA publicly addressed ImmunityBio, stating that despite prior warnings, the company continued to make misleading claims in its promotions, particularly in television advertising and podcasts. This led to a significant drop in ImmunityBio's stock price, which fell by over 21% in just a day, highlighting the potential impact of these allegations on shareholder value.

The law firm is urging any investor who purchased or otherwise acquired ImmunityBio securities during the designated class period to reach out to them to discuss the possibility of joining the class action. Individuals interested in making inquiries are encouraged to contact Danielle Peyton at [email protected] or call 646-581-9980. In your communication, you should include your contact details and the number of shares you acquired in ImmunityBio.

Importance of Participation

Participating in this class action not only holds the company accountable for its actions but also provides affected investors a platform to reclaim some of their losses. The Pomerantz Law Firm has an extensive track record of successfully recovering damages for class members and is committed to ensuring that victimized investors receive justice.

As the lawsuit progresses, it could bring to light critical information about ImmunityBio's operations and the decisions made by its executives. Investors should seriously consider their legal options, especially in scenarios where their investments have been adversely affected by the company's actions.

Conclusion

In conclusion, if you are among the investors who faced setbacks due to ImmunityBio's alleged misconduct, do not hesitate to explore participation in the ongoing class action lawsuit. Pomerantz LLP provides the necessary means to address your grievances and offers a valuable opportunity to hold the company accountable.

For more information, please visit www.pomerantzlaw.com and take prompt action by contacting the firm to secure your position in this significant legal engagement.